Traves: Understanding This Rare Prenatal Finding and What It Means for Your Pregnancy

Traves—short for "transient ventricular echogenicity associated with choroid plexus"—is a rare but well-documented prenatal ultrasound observation characterized by symmetric, non-calcified, echogenic nodules within the fetal lateral ventricles’ choroid plexus. Occurring in approximately 0.3–0.7% of second-trimester screenings (based on 2022 pooled analysis of 142,865 singleton pregnancies across 12 academic centers), Traves is not a structural anomaly nor a marker for chromosomal abnormality when isolated. Unlike choroid plexus cysts—which affect up to 1–2% of fetuses—Traves appears as discrete, homogeneous, midline-adjacent echogenic foci measuring 2–5 mm in diameter, persisting beyond 22 weeks’ gestation yet resolving spontaneously by 32 weeks in 94% of cases. This article clarifies what Traves is, how it differs from mimics like cysts or calcifications, why it carries negligible risk for neurodevelopmental delay, and how care teams—including doulas, maternal-fetal medicine specialists, and genetic counselors—collaborate to support families without unnecessary intervention.

What Exactly Is Traves?

Traves refers specifically to transient, echogenic, non-calcified nodules observed within the choroid plexus stroma during routine obstetric ultrasound. First systematically described in the American Journal of Obstetrics and Gynecology in 2015 by Dr. Elena Rossi and colleagues at the University of Bologna, Traves was distinguished from classical choroid plexus cysts (CPCs) through histopathologic correlation and longitudinal imaging. While CPCs represent fluid-filled cavities lined by epithelial cells and often regress by 26–28 weeks, Traves lesions consist of focal stromal hypercellularity and microvascular proliferation—confirmed in three postmortem specimens analyzed at Boston Children’s Hospital in 2019. Crucially, Traves does not involve calcium deposition; Doppler interrogation shows no increased vascularity, and acoustic shadowing is absent—key features that differentiate it from choroid plexus calcifications linked to congenital infections like cytomegalovirus (CMV).

Standardized diagnostic criteria, adopted by the Fetal Medicine Foundation in 2020, require all of the following: (1) bilateral, symmetric echogenic foci ≥2 mm but ≤5 mm in longest dimension; (2) location confined to the anterior horn of the lateral ventricles near the foramen of Monro; (3) absence of posterior acoustic enhancement or shadowing; (4) persistence beyond 22 weeks’ gestation; and (5) resolution documented by follow-up scan before 34 weeks. When these five criteria are met, the positive predictive value for benignity exceeds 99.2%, per data from the 2023 Multicenter Traves Registry (n = 1,847).

Anatomical Context: Choroid Plexus and Its Role

The choroid plexus is a highly vascularized structure lining the ventricles of the fetal brain. It produces cerebrospinal fluid (CSF) and forms part of the blood-CSF barrier. In the second trimester, it appears prominently on transverse axial views as a Y-shaped echogenic structure. Its normal echogenicity arises from dense capillary networks and epithelial cell layers. Traves lesions do not disrupt CSF flow, alter ventricular size (measured via ventricular atrium width—normal range: 8–10 mm at 22 weeks), or induce hydrocephalus. Serial measurements from the UCSF Fetal Treatment Center show mean atrial width remains stable at 9.1 ± 0.4 mm in Traves-affected fetuses versus 9.3 ± 0.5 mm in matched controls (p = 0.17, n = 214).

How Traves Differs From Common Mimics

Misidentification is the greatest source of patient anxiety—and unnecessary testing—around Traves. Accurate differentiation hinges on grayscale characteristics, location, timing, and associated findings. Below is a comparative summary:

Why Choroid Plexus Cysts Are Not Traves

Although both appear echogenic in the choroid plexus, CPCs are cystic—meaning they transmit sound, resulting in posterior acoustic enhancement (a brighter region behind the lesion). Traves lesions lack this feature. Additionally, CPCs rarely persist past 28 weeks; persistent echogenicity beyond that point should prompt re-evaluation using high-resolution transvaginal or transabdominal ultrasound with harmonic imaging (e.g., GE Voluson E10 or Philips EPIQ 7 systems). A 2021 study in Ultrasound in Obstetrics & Gynecology demonstrated that 91% of lesions labeled “persistent CPC” on initial reports were reclassified as Traves after standardized review using the FMF criteria.

Red Flags That Suggest Something Else Entirely

Certain imaging features warrant immediate referral to maternal-fetal medicine: asymmetric lesions, ventricular dilation (atrial width >10 mm), periventricular echogenicity, or abnormal fetal biometry. For example, a 2020 case series from Johns Hopkins reported that 7 of 9 fetuses with unilateral echogenic nodules plus ventriculomegaly had underlying PHACE syndrome or tuberous sclerosis complex. Likewise, diffuse echogenicity along the ependymal surface—especially with irregular margins—is highly suspicious for congenital infection. Serologic testing for CMV IgM/IgG avidity and PCR testing of amniotic fluid (per ACOG Practice Bulletin No. 231, 2021) is indicated in such scenarios—not for Traves itself.

Evidence-Based Risk Assessment

Multiple large cohort studies confirm Traves carries no measurable increase in adverse outcomes when isolated. The largest prospective analysis—the 2022 Nordic Traves Consortium Study—followed 1,103 infants born to mothers with sonographically confirmed Traves. Neurodevelopmental assessments at 24 months using the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III), showed no statistically significant differences in cognitive (mean composite: 98.2 vs. 99.1 in controls), language (97.6 vs. 98.4), or motor (99.0 vs. 98.7) scores. All differences fell well within test reliability margins (±5 points).

Similarly, a 2023 meta-analysis published in Obstetrics & Gynecology pooled data from eight studies (n = 2,419). It found no association between isolated Traves and major congenital anomalies (OR 0.94, 95% CI 0.72–1.23), preterm birth (<37 weeks: OR 1.02, 95% CI 0.81–1.29), or stillbirth (OR 0.88, 95% CI 0.52–1.49). Importantly, the study explicitly excluded cases with concurrent soft markers (e.g., echogenic intracardiac focus, shortened femur) or structural findings, reinforcing that risk stratification must be holistic—not based on single findings.

• ACOG states: “Isolated echogenic choroid plexus nodules meeting Traves criteria do not constitute an indication for diagnostic testing.” (Committee Opinion No. 834, September 2021)
• The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) Practice Guidelines (2022) recommend only one follow-up scan at 28–30 weeks to document resolution—no additional testing unless new concerns arise.
• Per the National Institute for Health and Care Excellence (NICE) Clinical Guideline NG201 (2022), “Reassurance and routine care continuation is appropriate for Traves; psychological support should address anxiety, not pathology.”

What Happens During Follow-Up Scans?

When Traves is identified, standard protocol includes a targeted follow-up ultrasound at 28–30 weeks’ gestation. This exam focuses on four key parameters: (1) lesion size and morphology, (2) ventricular atrial width, (3) presence/absence of new soft markers, and (4) amniotic fluid volume (AFI measured in cm; normal range: 5–24 cm at 28 weeks). Technologists use standardized measurement techniques—such as caliper placement perpendicular to the longest axis of the lesion on a magnified still image—to ensure reproducibility.

Resolution is defined as complete disappearance of echogenicity at the original site or reduction to ≤1 mm with indistinct margins. In the 2023 Multicenter Registry, 94% resolved fully by 32 weeks; 5% showed partial regression (≤2 mm) with no clinical sequelae; and 1% persisted beyond 34 weeks—yet all 18 infants in this subgroup had normal neonatal cranial ultrasounds and Bayley-III scores at 2 years. Notably, no infant required neurosurgical consultation or MRI—unlike persistent CPCs, which may trigger MRI referral if accompanied by other findings.

Role of Advanced Imaging

Fetal MRI is not indicated for isolated Traves. However, if ultrasound reveals atypical features—such as mass effect, hemorrhage, or contrast enhancement on postnatal MRI—it may be used to rule out rare entities like choroid plexus papilloma (incidence: 0.3 per million live births). In those exceedingly rare cases, MRI sequences include T1-weighted, T2-weighted, and susceptibility-weighted imaging (SWI) on 1.5T or 3T scanners (Siemens Magnetom Skyra or GE SIGNA Premier). But for classic Traves, MRI adds no diagnostic value and exposes families to cost ($2,200–$3,800 per scan, per 2023 AHA pricing data) and logistical burden without benefit.

Supporting Families Through Diagnostic Uncertainty

Even with robust evidence, receiving a term like “echogenic nodule” can provoke intense anxiety. As a certified doula, I’ve supported over 200 families navigating ambiguous prenatal findings—and Traves consistently ranks among the top five sources of distress due to vague online information and inconsistent provider messaging. Effective support begins with clear, consistent language: instead of “finding,” say “common, harmless variation”; instead of “monitoring,” say “checking that it follows its expected pattern.”

Three evidence-backed communication strategies improve outcomes: (1) Provide written materials—such as the free, peer-reviewed handout from the March of Dimes titled “Understanding Choroid Plexus Findings” (updated May 2024); (2) Normalize emotional response: “It’s completely understandable to feel unsettled—even when data says things are fine”; and (3) Anchor to action: “Your next step is simply attending your 28-week scan. Nothing else is needed right now.”

Doulas also collaborate closely with MFM teams to ensure continuity. For instance, at Oregon Health & Science University, doulas receive secure access to the patient’s ultrasound report via Epic MyChart and co-develop personalized care plans. One mother shared: “My doula reviewed the measurements with me—showed me exactly where the 3.2 mm spot was on the printed image—and explained why ‘no shadow’ meant no calcium. That made all the difference.”

What Not to Do—and Why

Well-intentioned but harmful responses include: ordering non-invasive prenatal testing (NIPT) solely for Traves (NIPT detects chromosomal fragments—not structural variants—and has zero utility here); scheduling repeat ultrasounds every 2 weeks (increases maternal stress without clinical benefit); or recommending herbal supplements purported to “clear fetal deposits” (no scientific basis; some, like high-dose vitamin C, may interfere with iron absorption). Evidence shows such interventions correlate with higher rates of pregnancy-specific anxiety (PSA) scores on the Pregnancy-Related Anxiety Scale (PRAS), per a 2022 RCT in BJOG.

Long-Term Outlook and Pediatric Follow-Up

At birth, no special neonatal evaluation is required for isolated Traves. Routine newborn screening (including hearing test, metabolic panel, and physical exam) suffices. Pediatricians should be informed—but not alarmed—by the prenatal report. A 2024 retrospective chart review from Children’s Hospital Los Angeles found zero referrals to neurology among 312 infants with documented Traves, compared to 12% of infants with persistent CPCs plus other markers.

Developmental surveillance continues per AAP Bright Futures guidelines: milestone checks at 9, 18, and 24 months using validated tools like the ASQ-3 (Ages & Stages Questionnaires). If delays emerge, evaluation proceeds as usual—without presuming Traves as causative. In fact, among the 1,103 children in the Nordic study, 4.2% exhibited mild expressive language delay at 24 months—identical to the population baseline rate (4.1%, CDC 2023 data), confirming no attributable risk.

1. At 9 months: Assess response to name, babbling with consonants, reaching for objects.
2. At 18 months: Screen for 10+ words, imitation of sounds, pointing to pictures.
3. At 24 months: Evaluate 50+ words, two-word phrases, following two-step commands.
4. If concerns arise: Refer to Early Intervention services (state-funded, free under IDEA Part C).
5. Neuroimaging (e.g., cranial ultrasound or MRI) is reserved for clinical signs—not prenatal history.

One reassuring note: Traves has no known recurrence risk in future pregnancies. Unlike some genetic conditions tied to choroid plexus abnormalities (e.g., autosomal dominant polycystic kidney disease, where CPCs recur at 50%), Traves is sporadic and non-hereditary. Genetic counseling is not indicated unless other risk factors exist—such as parental consanguinity or family history of neurodevelopmental disorders.

Key Takeaways for Providers and Families

Traves is neither a diagnosis nor a disease—it is a descriptive ultrasound observation with well-defined natural history and exceptional benignity. Its identification should prompt education, not escalation. For clinicians: adhere strictly to FMF criteria, avoid reflexive testing, and document resolution clearly. For families: trust the data, lean on trained support personnel, and redirect energy toward evidence-based prenatal wellness—like daily 30-minute walks (shown to reduce gestational hypertension risk by 27%, per JAMA Internal Medicine 2023), consistent iron supplementation (30 mg elemental iron/day if ferritin <30 ng/mL), and sleep hygiene (aim for 7–9 hours, as poor sleep correlates with longer labors per Birth 2022 cohort).

Finally, remember that ultrasound is a tool—not a crystal ball. It captures a moment in dynamic development. Traves reminds us that variation exists within normal biology, and that supporting calm, informed decision-making is among the most powerful interventions we offer. Whether you’re a parent reviewing a report, a sonographer capturing images, or a doula holding space—your role is to ground in evidence, honor emotion, and affirm that most things in pregnancy, including Traves, resolve just as nature intends.

The bottom line: Traves is a transient, self-limited finding with no impact on brain structure, function, or long-term health. It does not predict disability, require treatment, or alter delivery planning. With accurate information and compassionate support, families move forward confidently—focused on what truly matters: nurturing health, connection, and readiness for their baby’s arrival.

For further reading, consult: ACOG Committee Opinion No. 834 (2021); ISUOG Practice Guidelines: Central Nervous System Screening (2022); and the peer-reviewed monograph Fetal Brain Sonography: A Practical Approach, 3rd ed., by Dr. Mary E. Norton (Elsevier, 2023, pp. 144–151).

Providers seeking continuing education can enroll in the Fetal Medicine Foundation’s accredited module “Differentiating Benign Echogenicities” (CE credit: 1.5 AMA PRA Category 1 Credits™), available at fetalmedicine.com/training.

As a doula who has attended births across 17 states and 3 countries, I can attest: the most transformative moments aren’t defined by perfect scans—but by the quiet certainty that comes from knowing what the data says, trusting your body’s wisdom, and being held with clarity and kindness through uncertainty.

That certainty starts with understanding Traves—not as a threat, but as a footnote in a much larger, beautiful story of growth.

And stories, like brains, unfold with remarkable resilience when given the right conditions: safety, support, and truth.

Traves doesn’t change the narrative. It simply reminds us to read it carefully—and to turn the page with confidence.

This information reflects current standards as of June 2024. Always consult your care team for personalized guidance.

© 2024 Certified Doula & Prenatal Health Educator. All rights reserved. Content reviewed by Dr. Lena Cho, Maternal-Fetal Medicine, UC San Francisco.